Showing 1091-1100 of 20387 results for "".
Emerging Data in NTM Lung Disease: Potential Impacts and Ongoing Challenges
https://reachmd.com/programs/clinicians-roundtable/data-ntm-lung-disease-care-challenges-impacts/54380/Even as our understanding of nontuberculous mycobacterial (NTM) lung disease advances, major gaps remain, from defining meaningful treatment success to overcoming innate drug resistance. In this conversation with Dr. Alexandria May, Dr. David Griffith shares his perspective on how recent evidence isThe New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
https://reachmd.com/programs/cme/the-new-era-of-ras-targeting-mechanisms-evidence-and-clinical-integration-of-on-state-inhibitors/39770/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Breaking the Cycle: Understanding and Managing Inflammatory Memory in Psoriasis
https://reachmd.com/programs/clinicians-roundtable/breaking-the-cycle-understanding-and-managing-inflammatory-memory-in-psoriasis/32446/Inflammatory memory may influence symptom recurrence in psoriasis patients. Learn about how it works and strategies for promoting sustained remission.Achieving Success in IgAN & FSGS
https://reachmd.com/programs/cme/achieving-success-in-igan-fsgs/14677/Review underlying mechanisms of glomerulonephritis and sclerosis in patients with IgAN and FSGS and find out how emerging data may improve outcomes.When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
https://reachmd.com/programs/video-library/when-to-start-using-sglt2i-in-hfref-initiating-guideline-recommended-treatment-options/14734/This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".IBD and Biosimilars: What Healthcare Professionals Need to Know
https://reachmd.com/programs/gi-insights/ibd-and-biosimilars-what-healthcare-professionals-need-to-know/13835/Do you know how the approval of biosimilars will impact the treatment of inflammatory bowel disease? Hear from our experts and stay up to date!Investigating Inflammatory Mediators in Chronic Rhinosinusitis
https://reachmd.com/programs/deep-breaths-updates-chest/investigating-inflammatory-mediators-chronic-rhinosinusitis/13423/Learn more about the role of inflammatory mediators in chronic rhinosinusitis.Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
https://reachmd.com/programs/cme/navigating-today-and-shaping-tomorrow-in-ism-personalized-strategies-with-current-and-emerging-kit-inhibitors/54388/Explore the latest clinical evidence on current and emerging KIT tyrosine kinase inhibitors in indolent systemic mastocytosis to optimize patient care.Understanding the MOA of NEMLUVIO®: Targeting IL-31 Signaling in Neuroimmune Skin Diseases
https://reachmd.com/videos/nemluvio-peer-network/understanding-the-moa-of-nemluvio-targeting-il-31-signaling-in-neuroimmune-skin-diseases/37128/Watch Dr Peter Lio as he explains the role of IL-31, a key neuroimmune cytokine, in AD and PN and provides an in depth overview of the mechanism of action for NEMLUVIO®.Beyond Cognition: Managing Alzheimer’s as an Integrated Neurodegenerative–Neuropsychiatric Syndrome
https://reachmd.com/programs/cme/Beyond-Cognition-Managing-Alzheimers-as-an-Integrated-Neurodegenerative-Neuropsychiatric-Syndrome/54842/Examine integrated neurodegenerative and neuropsychiatric features of Alzheimer’s disease, including NPS biology and therapeutic strategies.